Neuropace Inc Stock Price, News & Analysis

NeuroPace, a medical device company based in Mountain View, California, is set to announce its financial results for the first quarter of 2023 on May 4, 2023. The report will be released after market close, followed by a conference call at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). The call will be accessible through a live and archived webcast on the company's website, ensuring replay availability for at least 90 days. NeuroPace specializes in innovative treatments for epilepsy, particularly with its RNS System, aimed at offering personalized, real-time solutions to patients suffering from drug-resistant epilepsy. This advanced platform represents a significant step forward in the care of patients with seizure disorders, promoting improved outcomes.

NeuroPace, a medical device company focused on improving the lives of individuals with epilepsy, announced participation in the 22nd Annual Needham Virtual Healthcare Conference. The presentation will take place on April 17, 2023, at 7:15 a.m. PT / 10:15 a.m. ET. A live webcast and an archived recording will be available on the company’s website. NeuroPace is renowned for its RNS System, a brain-responsive platform that delivers real-time treatment to help reduce or eliminate seizures. This innovative technology aims to enhance the standard of care for patients suffering from drug-resistant epilepsy and has potential applications for other brain disorders.

NeuroPace reported its fourth quarter and full-year financial results for 2022, highlighting a 16% increase in total revenue to $12.8 million compared to the previous year. Initial implant revenue rose 15% to $9.8 million, while revenue from DIXI Medical products contributed $1.6 million. However, the company saw a decline in replacement implant revenue to $1.4 million, down from $2.5 million year-over-year, which was anticipated. Gross margin for Q4 was 69%, a decrease from 73% the previous year. Full-year revenue was $45.5 million, a 1% growth, with a net loss of $47.1 million.

For 2023, NeuroPace projects revenue between $50 million and $52 million, driven by RNS System utilization.

NeuroPace, Inc. (Nasdaq: NPCE) announced it will report its financial results for the fourth quarter and full year of 2022 on March 2, 2023, after market close. The webcast of the conference call will begin at 1:30 p.m. PT / 4:30 p.m. ET, accessible on their website for live and archived listening.

The company focuses on innovative epilepsy treatment solutions, particularly with its RNS System, designed to provide personalized, brain-responsive therapy to patients experiencing drug-resistant epilepsy. NeuroPace aims to enhance care standards and patient outcomes in managing seizures.